SWShali Wang

Shali Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shali Wang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Di Chen

    Institute of Neuroscience School of Basic Medicine Chongqing Medical University Chongqing 400016 China

    1 shared publication
  • Feng Yang

    China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100070, China; Laboratory of Cognitive and Behavioral Disorders, Beijing Institute of Brain Disorders, Capital Medical University, Beijing 100069, China

    1 shared publication
  • Jing Zhao

    Institute of Neuroscience School of Basic Medicine Chongqing Medical University Chongqing 400016 China

    1 shared publication
  • Jingjing Shen

    Institute of Neuroscience School of Basic Medicine Chongqing Medical University Chongqing 400016 China

    1 shared publication
  • Junying Lan

    Basic and Translational Medicine Center China National Clinical Research Center for Neurological Diseases Beijing Tiantan Hospital Capital Medical University Beijing 100070 China

    1 shared publication
  • Peng Yu

    Chinese Institutes for Medical Research Capital Medical University Beijing 100069 China

    1 shared publication

Latest Publications

  • Open Access

    Behavioral Abnormalities, Cognitive Impairments, Synaptic Deficits, and Gene Replacement Therapy in a CRISPR Engineered Rat Model of 5p15.2 Deletion Associated With Cri du Chat Syndrome

    by Jingjing Shen, Yan Wang, Yang Liu, Junying Lan, Shuang Long, Yingbo Li, Di Chen, Peng Yu, Jing Zhao, Yongjun Wang, et al.

    The Cri du Chat Syndrome (CdCS), a devastating genetic disorder caused by a deletion on chromosome 5p, faces challenges in finding effective treatments and accurate animal models. Using CRISPR‐Cas9, a novel CdCS rat model with a 2q22 deletion is developed, mirroring a common genetic alteration in CdCS patients. This model exhibits pronounced deficits in social behavior, cognition, and anxiety, accompanied by neuronal abnormalities and immune dysregulation in key brain regions such as the hippocampus and medial prefrontal cortex (mPFC). The immunostaining and RNA‐seq analyses provide new insights into CdCS pathogenesis, revealing inflammatory and immune processes. Importantly, it is demonstrated that early gene replacement therapy with AAV‐ Ctnnd2 alleviates cognitive impairments in CdCS rats, highlighting the potential for early intervention. However, the effectiveness of this therapy is confined to the early developmental stages and does not fully restore all CdCS symptoms. The findings deepen the understanding of CdCS pathogenesis and suggest promising therapeutic directions.